Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24229699 | 0.89 | HRH3 (0.48) | HDAC6HDAC11HRH3CYP2D6HRH1 | |
| SCHEMBL23771247 | 0.78 | HDAC11 (0.63) | HDAC6HDAC11HRH1BCHEACHE | |
| SCHEMBL24229463 | 0.73 | BRAF (0.59) | HDAC6HDAC11 | |
| SCHEMBL3089244 | 0.73 | HRH3 (0.74) | HRH3CYP2D6HRH1 | |
| SCHEMBL29052789 | 0.71 | HRH3 (0.48) | HRH3CYP2D6HRH1 | |
| SCHEMBL6188078 | 0.71 | F10 (0.67) | — | |
| SCHEMBL24229494 | 0.71 | HRH3 (0.54) | HDAC6HRH3CYP2D6HRH1 | |
| SCHEMBL22639959 | 0.71 | NPSR1 (0.64) | HDAC6HDAC11 | |
| Hydrochloric Acid SCHEMBL6190611 | 0.71 | F10 (0.68) | — | |
| SCHEMBL5450398 | 0.70 | HRH3 (1.00) | HRH3CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| CN-116601150-A | Fused bicyclic RAF inhibitors and methods of use thereof | 爵士制药爱尔兰有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022023447-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | HDAC6 948/4885HDAC11 720/4885HRH3 3556/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | HDAC6 948/4885HDAC11 720/4885HRH3 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.